Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Investor Relations Home

To access The New England Journal of Medicine publication on the interim results from the ANNEXA-4 study of andexanet, visit: and NEJM ANNEXA-4 Supplement

Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
There are no past events to display.
Stock Quote
PTLA (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.20 (1.01%)
Data as of 10/26/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. We are advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhib... More >>

Recent NewsMore >>
10/25/16Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients
If Approved, Betrixaban, an FDA Fast Track-Designated Therapy, Would Be First Anticoagulant for Hospital to Home Prevention of VTE in this High-Risk Patient Population SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market betrixaban for extended-duration prophylaxis of venous thromboembolism (VTE) in a... 
Printer Friendly Version
10/13/16Portola Pharmaceuticals Supports “World Thrombosis Day” Campaign to Increase Awareness of Risks of Blood Clots
--Portola Working to Address Two Largest Remaining Unmet Needs in Thrombosis with Betrixaban and AndexXa™ (andexanet alfa)-- SOUTH SAN FRANCISCO, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) is committed to raising awareness of the incidence, risks and potentially life-threatening complications of thrombosis (blood clots) and is serving as a global partner for World Thrombosis Day, which is taking place today. According to the International Society on... 
Printer Friendly Version
09/13/16Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa™ (andexanet alfa) at Neurocritical Care Society 2016 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that Phase 3 clinical data and preclinical data from studies of the Company’s Factor Xa inhibitor antidote AndexXaTM (andexanet alfa) will be presented in poster sessions at the upcoming 14th Annual Neurocritical Care Society Meeting, which will take place from September 15-18 in National Harbor, Md. Additionally, results of a retrospective chart review on treatment patte... 
Printer Friendly Version
08/30/16Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXA-4™ Study of Factor Xa Inhibitor Antidote AndexXa™ (andexanet alfa) in Patients with Acute Major Bleeding
--AndexXa Rapidly Reversed Anticoagulant Effect of Factor Xa Inhibitors; Excellent or Good Hemostasis Was Achieved in 79 Percent of Patients Over 12 Hours-- --Data Presented in Late-Breaking Science Hot Line Session at European Society of Cardiology 2016 Congress and Published in New England Journal of Medicine-- --Webcast with ANNEXA-4 Executive Committee Members Today at 11 a.m. ET-- SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:P... 
Printer Friendly Version
08/26/16Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at European Society of Cardiology 2016 Congress
Company to Host Webcast of Investor Event with Drs. Stuart J. Connolly and C. Michael Gibson to Discuss Data on Tuesday, August 30 SOUTH SAN FRANCISCO, Calif., Aug. 26, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that interim results from its ongoing Phase 3b/4 ANNEXA™-4 trial of AndexXa™ (andexanet alfa), a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology (ESC) 2016 ... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.